Page URL:

Clinical-stage gene therapy company launched

11 November 2013
Appeared in BioNews 730

The Children's Hospital of Philadelphia (CHOP) has invested US $50 million in a biotech start-up in an effort to commercialise gene therapy.

Spark Therapeutics will use the investment to take over two clinical trials for inherited blindness and haemophilia B.

'The creation of Spark is the culmination of a decade-long commitment by CHOP and our founding team to drive the field of gene therapy forward during a time when many in the industry had moved away,' said Jeffrey Marrazzo, CEO of Spark Therapeutics.

Only one gene therapy has been commercialised in the West: uniQure's Glybera (reported in BioNews 680), but this has not yet been approved for use in the US.

Spark Therapeutics is likely to seek US Food and Drug Administration approval for gene therapy with the phase III study for treatment of inherited blindness caused by a mutation of the RPE65 gene.

This stage builds on earlier work that saw 12 patients with RPE65-related retinal degeneration demonstrate 'notable improvement in visual function', as reported by Spark Therapeutics. The company is also conducting early-stage clinical trials for haemophilia and studies to address neurodegenerative conditions, blood disorders and other forms of inherited blindness.

CHOP has taken a more hands-on approach in this venture with most of Spark Therapeutics' management and advisers coming from its Center for Cellular and Molecular Therapeutics.

'It's a bold move', Gary Kurtzman, managing director for healthcare at Safeguard Scientifics told The Philadelphia Inquirer. 'Based on the technology and the assets and the expertise, I think it's a very smart move'.

Children's Hospital of Phila. funds gene-therapy company |  24 October 2013
Gene therapy upstart launches with $50M and long-term commercial goals
Fierce Biotech |  22 October 2013
New Gene Therapy Company Launches
MIT Technology Review |  22 October 2013
Spark Therapeutics Launched with $50 Million in Financing to Advance Late- and Mid-Stage Gene  Therapy Programs with Clinical Proof of Concept (pdf)
Spark Therapeutics (press release) |  22 October 2013
24 April 2017 - by Kulraj Singh Bhangra 
A million-dollar gene therapy treatment for a rare blood disease will be withdrawn from the European market due to lack of demand...
2 February 2015 - by Dr Lucy Freem 
Biogen Idec has made an investment deal to develop gene therapy treatments for haemophilia A and B....
15 December 2014 - by Sean Byrne 
Pfizer has entered into a deal with biotech company Spark Therapeutics to conduct research into gene therapy for haemophilia B...
1 December 2014 - by Arit Udoh 
Glybera, the first gene therapy to go on sale in Europe, is set to cost €1.1m (£870,000) per patient, making it the world's most expensive drug...
2 December 2013 - by Dr Rachel Montgomery 
A biotech start-up that will develop genome-editing therapies has received US $43 million investment from three venture capital firms...
23 September 2013 - by Dr Anna Cauldwell 
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
9 September 2013 - by Siobhan Chan 
The first patients from two separate ongoing studies have been treated using gene and stem cell therapies to repair damage caused by heart attacks...
15 July 2013 - by Dr Nicola Davis 
A clinical trial of a gene therapy to treat children with two types of severe genetic disease has shown early signs of success...
5 November 2012 - by Dr Lucy Spain 
The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.